Quidel
QuidelOrtho Revenues up 8 Percent in Q2
On a conference call, its CEO said the future menu for the Savanna instrument will include respiratory panels, panels for other STDs, a panel for GI infections, and other tests.
QuidelOrtho Partners With BYG4lab for Lab Informatics
The partnership is intended to expand and strengthen QuidelOrtho's informatics offering across its diagnostics portfolio.
QuidelOrtho Recalls Triage Cardiac Panels Due to False Negative Results
The FDA has identified this as a Class I recall, the most serious type of recall, as use of these devices may cause serious injury or death.
FDA Grants De Novo Authorization to Sofia 2 System, COVID-19 Antigen Assay
The test is the first rapid antigen assay to be authorized by the FDA for marketing using the traditional premarket review process.
QuidelOrtho Preliminary Q4 Earnings Beat Estimates
The firm expects its Q4 non-COVID core revenues to increase approximately 18 percent and full-year core revenues to increase approximately 11 percent.
Oct 12, 2022
QuidelOrtho Reports Preliminary Q3 Revenues
Sep 7, 2022
Aug 18, 2022
QuidelOrtho Board Authorizes $300M Share Repurchase
Aug 5, 2022
QuidelOrtho Q2 Revenues Rise 34 Percent
Apr 8, 2022
Quidel Expects up to $1B in Q1 Revenues
Feb 17, 2022
Quidel Q4 Revenues Drop 21 Percent, Beat Estimates
Jan 10, 2022